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Introduction: The DDX21 RNA helicase has been shown to be a nucleolar and nuclear protein involved in
ribosome RNA processing and AP-1 transcription. DDX21 is highly expressed in colon cancer, lymphomas, and some
breast cancers, but little is known about how DDX21 might promote tumorigenesis.
Methods: Immunohistochemistry was performed on a breast cancer tissue array of 187 patients. In order to study the
subcellular localization of DDX21 in both tumor tissue and tumor cell lines, indirect immunofluorescence was applied.
The effect of DDX21 knockdown was measured by cellular apoptosis, rRNA processing assays, soft agar growth and
mouse xenograft imaging. AP-1 transcriptional activity was analyzed with a luciferase reporter and bioluminescence
imaging, as well as qRT-PCR analysis of downstream target, cyclin D1, to determine the mechanism of action for
DDX21 in breast tumorigenesis.
Results: Herein, we show that DDX21 is highly expressed in breast cancer tissues and established cell lines. A
significant number of mammary tumor tissues and established breast cancer cell lines exhibit nuclear but not nucleolar
localization of DDX21. The protein expression level of DDX21 correlates with cell proliferation rate and is markedly
induced by EGF signaling. Mechanistically, DDX21 is required for the phosphorylation of c-Jun on Ser73 and DDX21
deficiency markedly reduces the transcriptional activity of AP-1. Additionally, DDX21 promotes rRNA processing in
multiple breast cancer cell lines. Tumor cells expressing high levels of endogenous DDX21 undergo apoptosis after
acute DDX21 knockdown, resulting in significant reduction of tumorigenicity in vitro and in vivo.
Conclusions: Our findings indicate that DDX21 expression in breast cancer cells can promote AP-1 activity and rRNA
processing, and thus, promote tumorigenesis by two independent mechanisms. DDX21 could serve as a marker for a
subset of breast cancer patients with higher proliferation potential and may be used as a therapeutic target for a subset
of breast cancer patients.Introduction
Breast cancer is the second-most common cancer diag-
nosed in women in the United States. Multiple factors
have been found to contribute to breast cancer develop-
ment. Proliferation of breast cancer cells requires signals
from growth factors such as estrogen and epidermal
growth factor (EGF). These factors activate one of the
most important transcription factors in the nucleus, acti-
vating protein-1 (AP-1), which governs the transcription
of key molecules involved in cell cycle progression and* Correspondence: jweber@dom.wustl.edu
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unless otherwise stated.survival, as well as oncogene-induced transformation and
cancer cell invasion [1-4]. Previous studies have shown
that inhibition of AP-1 activity in breast cancer cells in-
duces cell cycle arrest and cell death as well as reduced
cell invasion in vitro and in vivo [5-8].
The AP-1 protein family primarily consists of homodi-
mers of Jun family members (including v-jun, c-jun, jun B,
Jun D) and heterodimers of the Jun family with Fos family
components (v-fos, c-fos, fosB, Fra-1, Fra2), or Jun family
with activating transcription factors (ATF2, ATF3, B-ATF)
[2,4]. Jun-Jun and Jun-Fos dimers preferentially bind to
the phorbol ester tumor promoter response element
(TRE) while Jun-ATF dimers prefer to bind to c-AMP-
responsive element (CRE) [9]. Jun/AP-1 can influence the
transcription of a plethora of proteins involved in prolifer-
ation, apoptosis, invasion and tumorigenesis [3]. By itself,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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as a proto-oncogene, albeit a weak one [10,11]. A strong
synergistic effect occurs between AP-1 and RasV12 alleles
in cell transformation and tumorigenesis [10,12]. An up-
stream mitogen-activated protein (MAP) kinase pathway
that activates Jun N-terminal kinase (JNK) can activate c-
Jun. JNK phosphorylates c-Jun on Ser63 and Ser73
[13,14], although phosphorylation on Ser73 of c-Jun plays
a more critical role than Ser63 in its activation [15] .
The DDX21 DEAD box RNA helicase has been recog-
nized as an important nucleolar protein involved in ribo-
some RNA processing as previous groups have found that
depletion of DDX21 results in significant reduction of 18S
and 28S rRNA levels in numerous cell types [16-18] and
DDX21 has been found to associate with 45S and 32S
rRNA species [18]. DDX21 mRNA expression has been
correlated with disease-free survival in breast cancer pa-
tients [19] and accumulation of DDX21 has been observed
in colon cancers and lymphomas [20,21]. DDX21 has also
been shown to interact with c-Jun and has been implicated
in c-Jun-mediated cellular differentiation [22]. Knockdown
of c-Jun causes a diffusion of exclusively nucleolar DDX21
to partially nuclear localization [18].
In this report, we found that DDX21 is highly expressed
in breast cancer tissues compared to normal breast tissue
and its expression is pivotal to maintain enhanced breast
cancer cell proliferation and growth. Surprisingly, a signifi-
cant number of breast cancer tissues and breast cancer
cell lines show nuclear localization of DDX21 protein. In
cells expressing high levels of c-Jun, such as MDA-MB-
231 cells, DDX21 associated with c-Jun, was required for
c-Jun phosphorylation, and was essential for endogenous
AP-1 activity. Moreover, DDX21 helicase activity was re-
quired to enhance the oncogenic activity of RasV12, sug-
gesting that DDX21 activities might provide requisite
functions during cellular transformation. Our results dem-
onstrate that DDX21 is an important growth and prolifer-
ation modifier that regulates oncogene-induced mammary
tumorigenesis, and implicate its potential therapeutic
value in breast cancers.
Material and methods
Cell culture
MCF-7, MDA-MB-231, SKBR3, MDA-MB-361, MDA-MB-
468, CAMA-1, and BT549 breast cancer cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and peni-
cillin-streptomycin. HCC70, HCC712 (obtained from Dr.
Matthew Ellis, Washington University), HCC1428, HCC
1806, ZR751, and T47D breast cancer cells were cultured in
complete RPMI media supplemented with 10% FBS and
penicillin-streptomycin. All cells were maintained at 37°C in
5% CO2. All cell lines were purchased from American Type
Culture Collection (ATCC) unless otherwise noted.Antibodies
Antibodies were obtained from Bethyl Laboratories,
Montgomery, TX, USA: anti-glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), anti-DDX21; Cell Signaling,
Danvers, MA, USA: anti-p53, anti-cyclin D1, anti-c-jun,
anti-phospho-c-jun (S73), anti-phospho-c-jun (S63); and
Santa Cruz Biotechnology, Dallas, TX, USA: anti-epithelial
growth factor receptor (EGFR), anti-tubulin, anti-Ras.
Immunoprecipitation and western blots
Cells were lysed in buffer containing 1% NP-40, 50 mM
Tris, pH 7.5, 150 mM NaCl, and supplemented with
protease and phosphatase inhibitor cocktails (Sigma-
Aldrich, St Louis, MO, USA). After incubation on ice for
10 minutes, cell lysates were sonicated to ensure complete
disruption. Lysates were then centrifuged for 10 minutes
at 13,000 rpm and supernatants were subjected to protein
quantification assay. For western blots, 50 μg of cell lysate
was loaded on a pre-cast mini-gel (Bio-Rad, Hercules, CA,
USA), followed by transferring to polyvinylidene fluoride
(PVDF) membrane (Merck Millipore, Billerica, MA,
USA). For immunoprecipitation, cell lysates were diluted
to 1 mg/ml with lysis buffer; 500 μg of total cell lysate was
incubated with 2 μg of indicated antibody for 2 hours at 4°
C, followed by addition of protein A/G Sepharose beads
and further incubated for 1 hour at 4°C. After centrifuga-
tion at 1,500 rpm for 2 minutes, beads were washed three
times with cell lysis buffer before analysis.
Plasmids
Full-length coding sequence for DDX21 was cloned from
early passage human BJ fibroblast total cDNA. Primers (for-
ward primer: TAGTACTCGAGCCACCA TGCCGGGAA
AACTCCGTAGT; reverse primer: CATGTGGATCCT
GAC TTGTCATCGTCATCCTTGTAATCTTGACCAAA
TGCTTTACTGAA) were used to clone the open reading
frame (ORF) of DDX21 into pLVX lentiviral vector at Hin-
dIII/ BamHI sites. Quick-change site-directed mutagenesis
kit (Stratagene, La Jolla, CA, USA) was used to carry out
the mutation K236R. Primers (forward primer: 5′-CGGA-
CAGGAACTGGGAGGACATT CTCCTTTGCC-3′; re-
verse primer: 5′-GGCAAAGGAGAATGTCCTCCCAG T
TCCTGTCCG-3′) were designed using free software from
Stratagene. Five different pLKO.1 plasmids containing
short hairpin RNA (shRNA) to target each of DDX21 were
obtained from the Genome Institute at Washington Uni-
versity. A pLKO.1 scrambled shRNA control plasmid was
purchased from Addgene, Cambridge, MA, USA.
Quantitative RT-PCR
Total RNA was extracted by NucleoSpin II (Clontech,
Mountain View, CA, USA) RNA isolation kit and was
converted into cDNA by SuperScript III first-strand syn-
thesis kit (Invitrogen, Carlsbad, CA, USA). Primers were
Figure 1 (See legend on next page.)
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Figure 1 DDX21 is overexpressed in breast carcinoma tissues. (A) Immunofluorescence was performed on a human tissue array including 67
cases of malignant breast cancer tissue specimen. Red color depicts DDX21 expression. Blue color depicts DAPI-stained nuclei. Typical images of
benign and malignant breast cancer tissues are shown. Left images were cropped from a larger field, while rights images were cropped from a smaller
field. All images were taken at 40X magnification. (B) Immunohistochemistry was performed on a human tissue array including 50 cases of invasive
ductal carcinoma with adjacent normal tissue samples. Brown color indicated positive DDX21 expression tissues. (C) Immunohistochemistry was
performed on a human tissue array including 70 cases of various stages of breast carcinoma. Typical images of positive-stained samples are shown.
DAPI, 4',6-diamidino-2-phenylindole.
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from Integrated DNA Technologies, Coralville, IA, USA.
The following primers were used in quantitative reverse-
transcriptase-polymerase chain reaction (qRT-PCR): for
cyclin D1, forward primer: 5′-AAGCTGTGCATCTA
CACCGA-3′; reverse primer: 5′-CTTGAGCTTGTTCAC
CAGGA-3′. For GAPDH, forward primer: 5′-CCCACTC
CTCCACCTTTGAC-3′; reverse primer: 5′-CATACCAG-
GAAATGAGCTTGACAA-3′. For all qPCR analysis, SYBR
green mix (Bio-Rad) was utilized.
[methyl-3H]-methionine labeling of rRNA
Equal numbers of cells were subjected to starvation in
methionine-free media containing 10% dialyzed FBS for
30 minutes. Cells were then treated with 50 μCi/mL
[methyl-3H]-methionine and chased in complete media
containing an excess of unlabeled methionine (10 μM)
for the indicated times. Samples were lysed in RNASolv
reagent (Omega Bio-Tek, Norcross, GA, USA) and
extracted RNA was separated on agarose-formaldehyde
gels and transferred to a Hybond XL membrane (GE
Healthcare, Little Chalfont, UK). The membrane was
cross-linked and sprayed with En3Hance (Perkin-Elmer,
Waltham, MA, USA) prior to autoradiography.
Immunofluorescence and microscopy
Cells were fixed with 10% formalin/10% methanol. Cells
were then incubated with rabbit anti-DDX21 (Bethyl La-
boratories) at a 1:200 dilution. Goat anti-rabbit rhoda-
mine was applied to facilitate the visualization of
DDX21 protein. To mark cell nucleoli, mouse anti-
nucleophosmin (NPM) or anti-upstream binding factor
(UBF) was used at a dilution of 1:100, followed by incu-
bation with goat anti-mouse fluorescein isothiocyanate
(FITC).
Apoptosis analysis
Apoptosis assays were performed with Vybrant apoptosis
kit #2 (Molecular Probes, Eugene, OR, USA) according
to the manufacturer’s protocol.
Soft agar assay
1.0 × 104 cells were mixed in 4.0 mL 0.3% agar/DMEM/
10% FBS as the top agar and plated into 60 mm plates
with 4.0 mL 0.6% agar/DMEM/10% FBS as the base agar.Plates were incubated at 37°C, checked every three days,
and fed with 2.0 ml 0.3% agar/ DMEM/10% FBS every
week. Colonies were photographed and counted two to
three weeks later.
Cell cycle analysis
Cells were trypsinized and washed with phosphate-
buffered saline (PBS). Cells were then resuspended in PBS
and 100% ethanol was added drop-wise to obtain a final
ethanol concentration of 75%. Cells were centrifuged at
2,000 rpm at 4°C for 2 minutes. Cells were then washed
with PBS and resuspended in PI working solution (PBS
containing 1% FBS, 250 μg/ml of RNase A, 30 μg/ml of
propidium iodide). Cells were filtered through a 35 μm
strainer cap (Becton Dickinson, Franklin Lakes, NJ, USA)
before being subjected to fluorescence-activated cell sort-
ing (FACS) analysis.
Immunohistochemistry
Human tumor tissue microarrays were purchased from
CYBRDI (CC08-11-007). This tissue microarray contains
self-paired tumor and adjacent normal tissues from 50
cases of stage I to stage III invasive ductal carcinoma. A
rabbit polyclonal anti-human DDX21 antibody (Bethyl La-
boratories) was used at 1:25. Tissue slides were deparaffi-
nized in xylene and rehydrated in a series of graded
alcohols and the antigen was retrieved in 0.01 M sodium
citrate buffer (pH 6.0) using a steamer. The sections were
then treated with 1% hydrogen peroxide in methanol for
30 minutes to exhaust endogenous peroxidase activity.
After a 1 h preincubation in 10% normal FBS to prevent
nonspecific staining, the samples were incubated with pri-
mary antibody at room temperature for 2 hours. Standard
protocol was then followed based on DAKO (Glostrup,
Denmark) Envision kit using polymer to amplify signals. A
separate breast tissue microarray was purchased from US
Biomax, Rockville, MD, USA (BR1503). This tissue micro-
array contains duplicate cores for three cases of normal
tissues, three fibroadenoma, two cystosarcoma phyllodes,
seven intraductal carcinomas and sixty invasive ductal car-
cinomas. Tissue slides were prepared as above. Rabbit
anti-DDX21 was applied at 1:25 dilution onto the tissue
slide and incubated at room temperature for 2 hours with
humidity. After PBS washes, secondary goat anti-rabbit
Alexa Fluor 594 was used at a dilution of 1:200 for half an
Figure 2 (See legend on next page.)
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Figure 2 DDX21 is highly expressed in proliferative breast cancer cell lines and is both nuclear and nucleolar. (A) A panel of 13 different breast
cancer cell lines and nontransformed MCF10A cells were analyzed for DDX21 protein expression by western blot analysis. A total of 50 μg of whole cell
extracts was used for analysis. Tubulin was used as a loading control. Quantitation of the signal was made by Image J software and normalized by tubulin
levels. (B) Equal numbers of the indicated breast cancer cell lines were plated and cell numbers were counted on a daily basis. Bars indicate standard
deviation from three separate experiments. Doubling times were estimated based on the growth curves. Doubling time of MDA-MB-231 cells was
determined separately. (C) MCF10A cells were cultured in regular DMEM media without insulin and EGF supplements for 48 hours. Cells were then fed
with DMEM complete media with either insulin alone, EGF alone or both insulin and EGF together for 24 hours. Cells were then harvested and total cell
lysates were subjected to western blot analysis with anti-DDX21 antibody and anti-tubulin antibody. (D) Above-mentioned growth factor-starved MCF10A
cells were treated with 100 ng/ml EGF containing complete media for the indicated time points. Whole cell extracts were subjected to western blot
analysis with anti-DDX21 antibody and anti-tubulin antibody. Standard error of the mean is indicated with fold-change. *, P <0.05. (E) HMECs and breast
cancer cell lines were subjected to immunofluorescence analysis with anti-DDX21 to detect cellular localization of DDX21 protein (red). Cell nuclei were
demarcated by DAPI (blue) and nucleoli were demarcated by UBF (green). DAPI, 4',6-diamidino-2-phenylindole; DMEM, Dulbecco’s modified Eagle’s
medium; EGF, epithelial growth factor; HMEC, human mammary epithelial cell; UBF, upstream binding factor.
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4',6-diamidino-2-phenylindole (DAPI) with mounting media
was applied and each tissue slide was checked under fluores-
cence microscope and images were taken. Both immunore-
active intensity and percentage of stained cells in different
areas of the same slide were analyzed according to criteria
described previously [23]. DDX21 expression was designated
as 0 = no staining; 1 =weak; 2 =moderate; and 3 = strong.
Additional points were scored as one, two, or three when
the percentage of positive cells was less than 25%, 25% to
50%, or greater than 50%, respectively.
Bioluminescence imaging
Nonobese diabetic/severe combined immunodeficient
(NOD/SCID) female mice were purchased from Charles
River Laboratories International, Inc., Wilmington, MA,
USA and received standard institutional care. They were
five weeks old at the time of surgery. MDA-MB-231 cells
stably expressing luciferase reporter (a kind gift from
Dr. Marc Diamond, Washington University in St. Louis)
were infected with lentiviruses encoding shScrambled
RNA or shRNA-DDX21. Two days postinfection, cells
were trypsinized, washed twice in PBS, counted, and
kept on ice prior to injection. Mice were anesthetized
and an inverted Y incision was made between the fourth
and fifth sets of nipples to expose the fourth mammary
fat pads bilaterally. 5 × 104 MDA-MB-231 cells were im-
planted into the fourth mammary glands. The final vol-
ume was 50 μl per mammary gland. The incision was
sutured and mice were monitored for tumor growth at
the indicated time points via bioluminescence imaging.
For bioluminescence imaging of live animals, previously
described mice were injected intraperitoneally with 150
μg/g D-luciferin (Biosynth, Naperville, IL, USA) in PBS,
anesthetized with 2.5% isoflurane, and imaged with a
charge-coupled device (CCD) camera-based biolumin-
escence imaging system (IVIS 100; Caliper, Hopkinton,
MA, USA; exposure time 10 to 300 seconds, binning 8,
field of view 12, f/stop 1, open filter). Signal was dis-
played as photons/sec/cm2/sr. Regions of interest (ROI)were defined manually around the abdomen, throat, and
whole body using Living Image and IgorPro Software
(Version 2.50) (Wavemetrics, Portland, OR, USA).
Mouse xenograft model
NUDE female mice were purchased from Charles River
Laboratories International, Inc. and received standard in-
stitutional care. They were five weeks old at the time of
surgery. For NUDE mice injection, alternate reading frame
(Arf)−/−mouse embryonic fibroblasts (MEFs) were in-
fected as indicated. Fibroblasts were trypsinized and re-
suspended in PBS at a concentration of 1 × 107 cells/ml.
Five-week-old NUDE mice were injected subcutaneously
with 1 × 106 cells along their flank, with sample sizes of
five mice per condition. Four weeks postinfection, tumors
were dissected, photographed and weighed.
Animal approval
The Animal Studies Committee of Washington Univer-
sity has approved the use of animals in conjunction with
this study through Animal Welfare Assurance # A-3381-
01 and Approval # 20130226 granted on November 18,
2013. All mouse experiments followed the guidelines of
the USDA Animal Welfare Act and the Public Health
Service Policy on the use of animals in research.
Results
DDX21 is highly expressed in breast carcinoma
We performed immunohistochemistry staining for DDX21
with several sets of human breast cancer tissue samples to
determine whether DDX21 overexpression occurs in breast
cancer. First, we performed immunofluorescence staining
for DDX21 with a breast tumor tissue array including 67
cases of various stages and subtypes of human breast can-
cer. Our results indicated that DDX21 was highly expressed
in 25% of the 67 cases of breast tumor tissues, while normal
breast tissue and benign tumors all exhibited very weak
staining for DDX21. Representative images of these tumor
tissues are shown in Figure 1A. Estrogen receptor (ER),
progesterone receptor (PR), human epidermal growth
Figure 3 (See legend on next page.)
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Figure 3 DDX21 knockdown in multiple breast cancer cell lines induces cell death and cell cycle arrest. (A) MCF-7 and T47D breast cancer cells
were either infected with shSCR or shRNA-DDX21 lentiviruses. Three days postinfection, cells were split and cultured for 48 hours. Typical images for the live
culture of the indicated transduced cells are shown. (B) MDA-MB-231 cells or HCC1806 cells were either transduced with shSCR or shRNA-DDX21
lentiviruses. Whole cell lysates were subjected to western blot analysis four days and five days postinfection with anti-DDX21 and anti-tubulin antibodies.
(C) MDA-MB-231 cells were either transduced with shSCR or shRNA-DDX21 lentiviruses. Five days postinfection, cells were then subjected to apoptosis
analysis by flow cytometry with Vybrant apoptosis kit after PI labeling of nuclei and FITC labeling of Annexin V. Percentage of live and dead cells are shown
in each quadrant. (D) Quantitation of live and apoptotic cells were calculated and graphed. (E) Above-mentioned MDA-MB-231 cells were subjected to
fixation and PI staining before flow cytometry to detect cell cycle distribution. Percentage of cells in each cell cycle phase is presented. (F) HCC1806 cells
were either transduced with shSCR or shRNA-DDX21 lentiviruses. Five days postinfection, cells were subjected to apoptosis analysis. Population of live and
dead cells is marked in each quadrant. (G) Quantitation of the live and apoptotic cells is graphed. FITC, fluorescein isothiocyanate.
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listed in Additional file 1: Table S1. DDX21 staining was
primarily observed in nuclei or in nucleolar structures
(Figure 1A). Strong DDX21 staining correlated with a high
rate of proliferation as detected by Ki67 on these tumor
tissues (Additional file 1: Table S1). However, not all of
Ki67-positive breast cancer tissues displayed strong
DDX21 staining, suggesting that DDX21 is not simply a
marker of proliferation. ER and PR status showed no cor-
relation with DDX21 expression levels, while DDX21
appeared to be highly expressed in a majority of HER2-
positive breast cancers (Additional file 1: Table S1). In
addition, we also performed a second tissue array with 50
pairs of nontumor and tumor tissues from unique breast
cancer patients (grade I to grade III). Nearly 20% of breast
tumor tissues exhibited stronger immunostaining of
DDX21 than the paired normal breast tissue in grade I to
grade III breast carcinomas (Figure 1B). Similarly, immu-
nostaining of a third breast cancer tissue array showed
that DDX21 was highly expressed in 16 out of 70 cases
(Figure 1C). Additionally, The Cancer Genome Atlas
(TCGA) datasets from recently sequenced human basal
breast cancer samples showed overexpression of DDX21
mRNA in 14/81 (17%) samples (cBioPortal). Taken to-
gether, DDX21 is highly expressed in a significant portion
of breast cancer tissues where it localizes to either nuclei
or nucleoli.
Nuclear and nucleolar DDX21 is highly expressed in
established breast cancer cell lines
We also analyzed DDX21 protein levels in a panel of
established breast cancer cell lines. All of these cancer
cells displayed detectable but varying DDX21 protein ex-
pression levels (Figure 2A). DDX21 protein levels were
significantly higher in cancer cell lines (compared to non-
transformed MCF10A cells) that proliferated faster, such
as HCC1806, SKBR3, MDA-MB-231 (Figure 2A and B).
Conversely, slower proliferating cell lines such as ZR751,
HCC70 and HCC1428, expressed much lower DDX21
levels (Figure 2A and B). However, tubulin levels may not
serve as the most accurate internal protein control, thus
allowing for some differences in our observed expression
patterns. In general, and although not absolute, we showthat there is a correlation between higher DDX21 levels
and overall cell proliferation rate.
In an effort to more accurately assess the connection
between proliferation rates and DDX21 expression, we
altered the proliferation rate of MCF10A cells through the
addition of defined mitogens. MCF10A cells are a nontu-
morigenic cell line derived from a human mammary gland
and its proliferation is dependent on growth factors such as
insulin and epidermal growth factor (EGF). Addition of in-
sulin to deprived MCF10A, which only slightly stimulated
cell proliferation, resulted in a minimal increase in DDX21
protein expression (Figure 2C). However, addition of EGF,
which induced a near maximal proliferation rate, resulted
in a significant increase in DDX21 protein expression that
was not further affected by insulin (Figure 2C). A time-
course analysis following EGF stimulation showed a rela-
tively rapid induction of DDX21 protein expression as early
as 2 hours poststimulation (Figure 2D). Thus, DDX21 ap-
pears to be a mitogen-induced protein whose expression is
indicative of proliferation status in vitro. This appears to
correlate with a report showing that DDX21 can be regu-
lated by activated MEK signaling [24].
We next performed immunofluorescence analysis to de-
termine the cellular localization of endogenous DDX21 in
the same panel of established breast cancer cell lines. Con-
sistent with the immunofluorescence results of primary
breast cancer tissues shown in Figure 1A, we found that
DDX21 protein was both nuclear and nucleolar. Specifically,
DDX21 localized to the nucleoplasm of T47D, MDAMB231,
MCF-7, SKBR3 and ZR751 cell lines (Figure 2E), while it lo-
calized to nucleoli in CAMA, HCC1806, HCC1428, HC
C712 and MDA-MB-468 as well as primary human mam-
mary epithelial cells (HMECs) (Figure 2E).
DDX21 is essential for breast cancer cell proliferation
and survival
Given the elevated protein expression of DDX21 in highly
proliferative breast cancer cell lines, we sought to deter-
mine whether DDX21 was an essential protein for cell
proliferation and survival. We utilized multiple shRNAs tar-
geting endogenous human DDX21 to effectively lower
DDX21 protein expression. Following successful knock-
down of DDX21, we observed a consistent two-to-threefold
Figure 4 (See legend on next page.)
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Figure 4 DDX21 is important for the tumorigenicity of breast cancer cells in vitro and in vivo. (A) T47D, MCF-7 and SKBR3 cells were transduced with
either shSCR or shRNA-DDX21 lentiviruses. DDX21 levels were detected by western blot analysis after lentiviral knockdown. Tubulin was used as a loading
control. (B) Above-mentioned cells were also subjected to soft agar analysis after plating 1 × 104cells in each 60 mm dish. Typical image is shown after
culturing for two weeks. (C) Quantitation of colony numbers in the soft agar assay is graphed; error bars were taken from triplicates. (D) A group of five SCID
mice were injected at the mammary gland on both sides with MDA-MB-231-luciferase reporter cells transduced with either shScrambled or with shDDX21
(50,000 cells per injection). Mice were allowed to recover from the surgery and bioluminescence imaging was performed from two weeks to nine weeks. A
representative mouse from each group is shown at the indicated time points. Data presented show the mean ± standard deviation from five different mice
in each group. SCID, severe combined immunodeficiency.
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T47D cells revealed an increase in apoptotic cells following
DDX21 knockdown as evidenced by smaller and more re-
fractive cells (Figure 3A). Reduction of DDX21 with mul-
tiple shRNAs in MDAMB231 and HCC1806 cells was
confirmed by western blot analysis (Figure 3B). Annexin V
staining was used to mark apoptotic cells and results
showed a clear increase in apoptotic MDA-MB-231 cells,
where DDX21 was primarily nuclear, after DDX21 knock-
down (Figure 3C and 3D). Cell cycle analysis revealed a
slight, but reproducible, reduction in S phase that coincided
with either an increase in G1 or G2/M phases (Figure 3E).
Consistent with these results, knockdown of DDX21 in
HCC1806 cells, where DDX21 localized primarily to nucle-
oli, resulted in dramatic increases in cell death. However,
Annexin V and PI staining of HCC1806 cells indicated that
DDX21 knockdown in HCC1806 cells resulted in necrotic
cell death rather than apoptosis (Figure 3F and 3G). Taken
together, these results show that elevated DDX21 expres-
sion is required in order to maintain the viability and cell
cycle progression of highly proliferative breast cancer cells.
DDX21 is required for the tumorigenicity of breast cancer
cells in vitro and in vivo
To assess the long-term effects of DDX21 deficiency on
proliferation and tumorigenesis, we utilized multiple
shRNAs targeting endogenous human DDX21 to effect-
ively knock down DDX21 protein expression in three
highly proliferative breast cancer cell lines (Figure 4A).
DDX21 knockdown had a dramatic impact on anchorage-
independent cell growth with lower levels of DDX21
resulting in impaired growth in semi-solid soft agar
(Figure 4B and C) and indicating that DDX21 might be re-
quired for mammary cell tumorigenicity. In addition, we
also performed xenograft implants to assess in vivo tumori-
genesis. Severe combined immunodeficiency (SCID) mice
were injected with equal numbers of MDA-MD-231 cells
carrying a luciferase reporter and either shScrambled or
shDDX21 constructs. At nine weeks post-surgery, the five-
shScrambled mice developed steadily increasing signals that
were significantly higher than the five-shDDX21 mice
(Figure 4D). These results indicate a clear requirement for
DDX21 protein expression during breast cancer tumorigen-
esis in vitro and in vivo. Our results are also consistent withprevious findings that MCF-7 cells (high DDX21) grow
significantly faster in vivo than ZR-75-1 cells (low
DDX21) [25].
DDX21 modulates AP-1 activity
To begin to understand the molecular function of
DDX21, we turned to one of its only known interacting
partners, c-Jun [22]. We first examined whether DDX21
interacted with c-Jun in our panel of established breast
cancer cell lines. We found that c-Jun was highly
expressed in MDA-MB-231 and to a lesser extent in
BT549 cells while the remaining lines had very low levels
of c-Jun protein expression (Figure 5A). Protein extracts
from MDA-MB-231, MCF-7 and SKBR3 cells were sub-
jected to co-immunoprecipitation assays using anti-c-Jun
or anti-DDX21 antibodies. We determined that indeed
DDX21 associated with c-Jun in each of the cells in recip-
rocal immunoprecipitations (Figure 5B and C). Addition-
ally, these interactions were enriched when nuclei were
isolated prior to performing the immunoprecipitations
(Figure 5D), arguing that the interaction of c-Jun and
DDX21 in these cells is occurring in the nucleoplasm.
As c-Jun is a critical component of the AP-1 transcrip-
tion factor, we hypothesized that DDX21 might some-
how modulate AP-1 activity in breast cancer cells. To
test this hypothesis, we knocked down DDX21 expres-
sion in MDA-MB-231 cells and assayed c-Jun activation
using antibodies that recognized the phosphorylation of
c-Jun on two critical serine residues, Ser63 and Ser73
[12]. DDX21-depleted cells displayed significantly re-
duced levels of phosphorylated c-Jun on Ser73, the pri-
mary site for c-Jun activation, while maintaining
consistent total c-Jun levels (Figure 6A).
Importantly, AP-1 activity governs the transcriptional in-
duction of cyclin D1 to promote the enhanced proliferation
of established breast cancer cells [1]. Consistent with our
connection between DDX21 and c-Jun phosphorylation
status, knockdown of DDX21 resulted in a significant de-
crease in cyclin D1 protein expression (Figure 6A). Simi-
larly, expression of EGFR, another target of AP-1 [4], was
also reduced at the protein level by up to 30 to 40% in all
three DDX21 knockdown samples (Figure 6A) as well as at
the mRNA level (Figure 6C). As expected, cyclin D1 mRNA
levels were substantially reduced in DDX21 knockdown
Figure 5 c-Jun interacts with DDX21 in breast cancer cell lines. (A) Panel of breast cancer cell lines was screened by western blot analysis with
anti-c-Jun antibody. Fifty μg of whole cell lysates were subjected to the analysis and tubulin is used as a loading control. Quantitation of the signal was
made by Image J software and normalized by tubulin levels. (B) 500 μg of protein lysates were subjected to immunoprecipitation with anti-c-Jun
antibody with mouse IgG as a negative control, 25 μg of SKBR3 cell lysate was used as input control. Immune complexes were blotted with
anti-DDX21 and anti-c-Jun. (C) Reciprocal immunoprecipitation was also performed with the above-mentioned cell lysates. Western blot analysis was
performed to confirm the association between c-Jun and DDX21 in breast cancer cell lines. (D) c-Jun immunoprecipitation was performed on purified
nuclear lysates from the indicated cell lines. Western blot analysis was performed to confirm the association between c-Jun and DDX21.
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http://breast-cancer-research.com/content/16/5/449cells (Figure 6B), underscoring the transcriptional relation-
ship between DDX21 and known AP-1 targets. To more
directly assess the endogenous AP-1 transcriptional activity
in DDX21-depleted cells, a firefly luciferase reporter was
utilized. We first infected MDA-MB-231 cells with lentivi-
ruses encoding an AP-1-firefly luciferase reporter, and then
infected these transduced cells with a second lentivirus en-
coding the shScramble or shRNA-DDX21. Cells were then
transiently transfected with a plasmid encoding a Renillaluciferase reporter to control for transfection efficiency.
After normalization to Renilla luciferase activity, we mea-
sured a 40 to 50% reduction in AP-1 activity in DDX21
knockdown cells (Figure 6D). Correspondingly, we ob-
served a reduction in AP-1-directed luciferase activity in
SKBR3 cells following DDX21 knockdown (Figure 6D).
Taken together, our results demonstrate that DDX21,
through its interaction with c-Jun, is required for AP-1 ac-
tivity and its ability to transcriptionally induce cyclin D1
Figure 6 (See legend on next page.)
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Figure 6 DDX21 modulates AP-1 activity in MDA-MB-231 cells. (A) MDA-MB-231 cells were either infected with shSCR or shRNA-DDX21 lentiviruses.
Whole cell lysates were subjected to western blot analysis with the indicated antibodies with tubulin as an internal control. Standard error of the mean is
indicated with fold-change. *,P <0.05. (B) RT-PCR analysis was performed for cyclin D1 mRNA levels after normalization with GAPDH mRNA levels. Error bars
were taken from three independent experiments. *,P <0.001. (C) RT-PCR analysis was performed for EGFR mRNA levels after normalization with GAPDH
mRNA levels. Error bars were taken from three independent experiments. *,P <0.005. (D) MDA-MB-231 and SKBR3 cells were infected with AP-1 reporter
lentiviruses to detect endogenous AP-1 activity. After verification of AP-1 luciferase activity, these cells were infected with either shSCR or shRNA-DDX21.
Two days postinfection, equal numbers of cells were transfected with pGL-Renilla-luciferase plasmids. Equal numbers of cells were then analyzed for both
firefly and Renilla luciferase activity. Data presented is firefly luciferase activity after normalization with Renilla luciferase and then further normalized to shSCR
control. *,P <0.001 (n =3). (E) MDA-MB-231 cells infected with shSCR or shRNA-DDX21 lentiviruses were stained with antibodies recognizing NPM and
visualized by indirect immunofluorescence. DAPI stain was used to mark nuclei. Images are representative of over 100 cells for each condition. DAPI,
4',6-diamidino-2-phenylindole; EGFR, epithelial growth factor receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NPM, nucleophosmin;
RT-PCR, reverse transcriptase-polymerase chain reaction.
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http://breast-cancer-research.com/content/16/5/449and EGFR. To rule out the possibility that these findings
occurred because of a loss in nucleolar integrity, we stained
nucleoli from MDA-MB-231 cells with antibodies recogniz-
ing nucleophosmin (NPM). We observed no change in nu-
cleolar staining of NPM when comparing shSCR and
shDDX21 cells (Figure 6E), indicating an intact nucleolus in
all cells.
Nucleolar DDX21 is required for rRNA processing in
breast cancer cells
DDX21 was originally identified as a protein that might be
involved in rRNA processing based solely on its nucleolar
localization. To determine whether DDX21 is a critical
component of rRNA processing in our breast cancer sys-
tem where DDX21 is primarily nucleolar, we first per-
formed an rRNA pulse-chase assay with HCC1806 cells in
which DDX21 localizes to the nucleolus. As shown by
Figure 7A, DDX21 knockdown caused the accumulation
of the rRNA precursor 47S and reduced the total levels of
mature 28S and 18S rRNAs, indicating a requirement for
DDX21 in the initial processing of the 47S transcript. To
determine whether other rRNA processing steps were af-
fected by DDX21 reduction, we followed rRNA processing
for 50 minutes. DDX21 knockdown primarily inhibited
rRNA processing at the initial 47S processing step and did
not result in the accumulation of other downstream inter-
mediates that were not processed properly (Figure 7B),
again underscoring the role of DDX21 in the first step 47S
rRNA processing.
DDX21 RNA helicase activity is required for efficient
RasV12 cell transformation
Ras is a frequent target for mutation in human cancers.
Constitutive activation of Ras through activating muta-
tions, such as RasV12, leads to oncogenic transformation
of immortalized mouse fibroblasts [26]. C-Jun has been
shown to synergize with oncogenic RasV12 to induce
tumor formation [12,27]. To determine whether DDX21
enhances RasV12’s transforming activity, immortalized
(Arf-null) MEFs were consecutively infected with lenti-
viruses encoding wild-type DDX21 and retrovirusesencoding oncogenic RasV12, and then shRNA for mouse
endogenous DDX21. Conversely, Arf-deficient MEFs
were infected with lentiviruses encoding a helicase-
defective DDX21 mutant at lysine 236. Lysine 236 re-
sides in the ATP-binding motif of DDX21 and mutation
of lysine 236 to arginine (K236R) disrupts its ATP-
binding activity and severely attenuates its helicase ac-
tivity. Protein expression levels of DDX21 and Ras are
shown in Figure 8A. The tumorigenicity of RasV12 was
then analyzed with various levels of DDX21 by soft agar
assay. Reduction in endogenous DDX21 resulted in a
significant attenuation in soft agar colony formation
and wild-type DDX21 overexpression rescued the ability
of RasV12-transformed Arf-null MEFs to grow in soft
agar following endogenous DDX21 knockdown
(Figure 8B). However, the helicase dead mutant K236R
DDX21 failed to restore the transforming activity of
RasV12 (Figure 8B), implying that DDX21 helicase activ-
ity was required for effective RasV12 transformation. To
determine whether this phenotype could be observed
in vivo, the above-mentioned cells were injected into
the flanks of NUDE mice and the resulting tumors were
excised after four weeks. Consistent with our in vitro
results, only wild-type DDX21 was able to rescue the
tumorigenicity of RasV12 (Figure 8C and D), indicating
that DDX21 and its RNA helicase activity is pivotal
to maintain RasV12 transforming activity in vivo. Im-
portantly, nucleolar localization of DDX21 per se was
not sufficient for its function in promoting cellular
transformation as the K236R helicase dead mutant lo-
calized to nucleoli (Figure 8E) but failed to rescue
transformation.
Discussion
We report here that DDX21 is overexpressed in a signifi-
cant number of human breast cancers (up to 25%). Its over-
expression preferentially occurs in highly proliferative
breast cancer tissues and cells. Apart from its predominant
nucleolar localization in many breast cancer cells, we also
found that DDX21 localized to the nucleoplasm in a signifi-
cant number of breast cancer tissues as well as established
Figure 7 Nucleolar DDX21 promotes rRNA processing in breast
cancer cells. (A) HCC1806 cells were infected with shSCR or
shRNA-DDX21, two days postinfection, cells were pulsed with
[3H-methyl] methionine and chased for 1 hour. Total RNA was
extracted and analyzed for 47S, 32S, 28S and 18S rRNA levels.
Methylene blue-stained membrane is also shown at the bottom.
(B) HCC1806 cells were infected with shSCR or shRNA-DDX21, two
days postinfection, cells were pulsed with [3H-methyl] methionine
and chased for 0, 25 and 50 min. Total RNA was extracted and
analyzed for 47S, 32S, 28S and 18S rRNA levels. Methylene
blue-stained membrane is also shown at the bottom.
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the nuclear localization of DDX21, since in MDA-MB-231
cells that had the highest c-Jun levels, DDX21 predomin-
antly localized to the nucleus. This suggests that other
regulatory mechanisms might influence the subcellular
localization of DDX21. This localization is significant
because in these cells we found an association between
DDX21 and the c-Jun transcription factor. Originally
thought to play a role in rRNA processing due to its nucle-
olar localization [28], nucleoplasmic localization of DDX21
implies functions outside of rRNA processing. This was re-
cently demonstrated when DDX21 was found to form a
complex with DDX1 and DHX36 to sense double-stranded
RNA in the cytoplasm of dendrite cells [28]. Our results
point to its important function in the nucleus: to promote
the activation of c-Jun in epithelial cells. DDX21 sets the ac-
tivation state of nuclear AP-1 complexes and facilitates its
transcriptional activity toward key players in cell prolifera-
tion such as cyclin D1. Particularly, in MDA-MB-231 cells
where endogenous c-Jun levels are high, DDX21 expression
appears to be critical for maintaining AP-1 transcriptional
activity. Short hairpins targeting endogenous DDX21 re-
sulted in lowered DDX21 and concomitant decreases in c-
Jun Ser73 phosphorylation, a phospho-residue required for
AP-1 activation. While it is uncertain how DDX21 might
enhance c-Jun phosphorylation through its interaction with
c-Jun, lower DDX21 protein expression clearly led to a sig-
nificant reduction in classic AP-1 transcriptional targets
such as cyclin D1 and EGFR.
Large-scale genome sequencing of human cancers has
revealed that cancer cells possess large numbers of gen-
etic and epigenetic alterations [29-31]. While many of
these alterations are likely to be random due to the gen-
omic instability of tumor cells, only a few are regarded
as true oncogenes that drive the cancer phenotype [32].
However, increased dependence of cancer cells on nor-
mal cellular functions also plays essential roles for main-
taining cancer cell phenotype. These genes are often
called non-oncogenes in reference to their requirement
for cellular transformation while not possessing trans-
forming activities alone [33,34]. Here, we have shown
that DDX21 indeed could fall into this category of genes
whose activities are required but not sufficient for
Figure 8 (See legend on next page.)
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Figure 8 DDX21 helicase activity is required for enhanced RasV12 transformation. (A) Arf-null MEFs were infected with lentiviruses that encode
either wild-type human DDX21 or K236R mutant DDX21 with empty vector as a control. Infected cells were then selected in hygromycin-containing media
(500 μg/ml) for three days. Cells were then plated and infected with retrovirus encoding RasV12 or empty vector, and selected in puromycin (4 μg/ml) for
two days. Cells were then infected with lentiviruses targeting mouse endogenous DDX21 (shRNA-DDX21) with shSCR as a control. Four days postinfection,
whole cell lysate for each sample was then analyzed by western blot with anti-DDX21 antibody, anti-tubulin antibody and anti-Ras antibody. (B) For
above-mentioned cells, 1 × 104 cells were plated into soft agar for colony-forming assay. Quantitation for the number of colonies was shown. Data pre-
sented is the average number of colonies from triplicate plates. Bars indicate standard deviation from each triplicate. *, P <0.001. (C) Above-mentioned cells
(1 × 106 per condition) were injected into the flanks of NUDE mice, after four weeks, mice were sacrificed and tumor were dissected and photographed.
(D) Tumors from each group were weighed and graphed. (E) Above-mentioned cells were fixed and stained with antibodies recognizing DDX21 and
visualized by indirect immunofluorescence. DAPI was used to mark nuclei. Images are representative of over 100 cells counted for each condition. DAPI,
4',6-diamidino-2-phenylindole; MEFs, mouse embryonic fibroblasts.
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http://breast-cancer-research.com/content/16/5/449cellular transformation. DDX21 expression is high in
many primary human breast tumors [19] (and herein)
and established breast cancer cell lines. Knockdown of
DDX21 resulted in dramatic increases in cell death in
numerous breast cancer cell lines. DDX21 expression
was required to maintain breast cancer survival and
proliferation in an in vivo mouse mammary gland. Im-
mortal fibroblasts also required DDX21 expression to be
efficiently transformed by oncogenic RasV12 alleles. To-
gether, these results point to an essential role for DDX21
in tumor cell survival, proliferation, and transformation
through two independent activities: rRNA processing
and c-Jun activation. However, DDX21 alone is not suffi-
cient to transform immortal cells, underscoring its po-
tential role as a non-oncogene. Our results strengthen
the concept that has been posited in recent years: that
cancer cells rely on non-oncogenes in order to maintain
and even enhance their tumorigenic phenotype.
The family of DEAD/DEAH box RNA helicases has
recently emerged as a large family (54 members) of
multifunctional proteins involved in various steps of
RNA and DNA metabolism [35-38]. It is becoming ap-
parent that many of these helicases perform functions
that are either fundamental in many basic cellular pro-
cesses such as rRNA synthesis or are more specific in
promoting cancer cell growth and proliferation. Even
though their detailed molecular mechanisms remain
largely undiscovered, our report on DDX21 function un-
derscores the potential importance and diversity of
DEAD/DEAH helicases in promoting cancer and cer-
tainly warrants a broader evaluation of the activities of
this protein family.
Conclusions
In this study, we found DDX21 overexpressed in highly
proliferative primary breast carcinomas. DDX21 was
found to localize to the nucleus and nucleolus in a num-
ber of breast cancer tissues as well as in numerous
established breast cancer cell lines. In multiple breast
cancer cell lines, DDX21 protein knockdown triggered
cell cycle arrest as well as massive cell death and caused
a significant reduction in anchorage-independent cellgrowth in vitro as well as in vivo. We found that nuclear
DDX21 interacted with the activating protein (AP-1)
component, c-Jun. DDX21 was required for c-Jun Ser73
phosphorylation and activation of AP-1 transcriptional
activity, while nucleolar DDX21 promoted cell growth
by enhancing rRNA processing. Furthermore, DDX21
RNA helicase activity was required for effective RasV12
transformation. These data highlight the importance of
DDX21 in breast cancer cell proliferation and transform-
ation through its promotion of AP-1 activity, rRNA pro-
cessing and its cooperation with known oncogenes.
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